Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lifecore Biomedical

This article was originally published in The Gray Sheet

Executive Summary

FDA Medical Devices Dispute Resolution Panel (MDDRP) review will be sought following device center's "not approvable" determination for Lifecore's Gynecare Intergel ferric hyaluronate adhesion prevention solution. The firm had submitted an amendment to its March 1999 premarket approval application in June 2000, following a recommendation against approval from FDA's General and Plastic Surgery Devices Advisory Panel last January (1"The Gray Sheet" Jan. 17, 2000, p. 4). The MDDRP, mandated by the FDA Modernization Act of 1997, had its inaugural meeting Oct. 31, 2000 (2"The Gray Sheet" Nov. 6, 2000, In Brief)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel